Parkinson's disease, Daniel Barenboim
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
21hon MSN
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
11h
Hosted on MSNOzzy Osbourne's Heartbreaking Health Update: Inside the Rocker's Debilitating Struggle With Parkinson's DiseaseWhat is Ozzy Osbourne's health situation? Ozzy lives with Parkinson's disease, and has had numerous surgeries over the ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results